 MONROVIA, Calif.--BUSINESS WIRE--Xencor, Inc. NASDAQ: XNCR, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb bispecific antibody programs and the IL-12-Fc cytokine program at the American Association for Cancer Research AACR Annual Meeting, being held virtually April 10-15, 2021. Abstracts for these poster presentations ar 